Skip to main content
. 2010 Jun 7;42(7):477–483. doi: 10.3858/emm.2010.42.7.049

Figure 3.

Figure 3

IQGAP1 promotes in vivo tumorigenic growth of HepG2 cells. (A) Immunocompromised nude mice received subcutaneous injections of equal numbers (1 × 105) of HepG2/V, HepG2/I, and HepG2-sih cells and the rate of appearance of palpable primary tumors was examined. (B) Final volume of tumors derived from subcutaneous implants. Primary tumor volumes were measured 60 days after transplantation of HepG2/V, HepG2/I, and HepG2-sih cells. Data represent the mean ± S.D, n = 8 animals/group.